Cat. No.: HY-126193

JS-K

Name: JS-K
Brand: MedChemExpress
SKU: HY-126193
Price: 150.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Avis client

Based on 1 Customer Validation

JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH. JS-K induces reactive oxygen species (ROS) to mediate apoptosis. JS-K induces autophagy. JS-K inhibits invasion. JS-K has a broad spectrum anti-proliferative activity in cancer cells. JS-K reduces tumor volume and causes necrosis of implanted tumors in mice.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.59%
CAS No.: 205432-12-8
Formule: C₁₃H₁₆N₆O₈
Masse moléculaire:384.30

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

JS-K Chemical Structure

CAS No.: 205432-12-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform NO Synthase :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.8 μM Compound: JS-K	Antiproliferative activity against human 786O cells after 72 hrs by MTT assay Antiproliferative activity against human 786O cells after 72 hrs by MTT assay	[PMID: 18930407]
A2780	IC₅₀	>20 μM Compound: JS-K	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 36470106]
A2780	IC₅₀	0.63 μM Compound: 19	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 25350923]
A549	IC₅₀	0.69 μM Compound: 6; JS-K	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
A549	IC₅₀	1.26 μM Compound: 19	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25350923]
A549	IC₅₀	1.5 μM Compound: JS-K	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 18930407]
A549	IC₅₀	2.11 μM Compound: JS-K	Anticancer activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay Anticancer activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay	[PMID: 32156499]
A549	IC₅₀	2.313 μM Compound: JS-K	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29501947]
A549	IC₅₀	6.53 μM Compound: JS-K	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay relative to control Antiproliferative activity against human A549 cells after 48 hrs by MTT assay relative to control	[PMID: 29220794]
A549/TR	IC₅₀	1.987 μM Compound: JS-K	Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay	[PMID: 29501947]
B16	IC₅₀	1340 nM Compound: 1; JS-K	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 29420887]
Bel-7402	IC₅₀	5.17 μM Compound: JS-K	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 23617697]
BT-474	IC₅₀	3.66 μM Compound: JS-K	Anticancer activity against human BT474 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay Anticancer activity against human BT474 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay	[PMID: 32156499]
Caco-2	IC₅₀	2.6 μM Compound: JS-K	Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay	[PMID: 18930407]
CCRF-CEM	IC₅₀	0.89 μM Compound: JS-K	Anticancer activity against human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay Anticancer activity against human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay	[PMID: 32156499]
ES-2	IC₅₀	>20 μM Compound: JS-K	Antiproliferative activity against human ES2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human ES2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 36470106]
HCT-116	IC₅₀	0.5 μM Compound: 6; JS-K	Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
HCT-116	IC₅₀	0.7 μM Compound: JS-K	Antiproliferative activity against human HCT 116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT 116 cells after 72 hrs by MTT assay	[PMID: 18930407]
HCT-116	IC₅₀	3.75 μM Compound: JS-K	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
HCT-116	IC₅₀	4.86 μM Compound: JS-K	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay relative to control Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay relative to control	[PMID: 29220794]
HCT-15	IC₅₀	0.6 μM Compound: JS-K	Antiproliferative activity against human HCT-15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT-15 cells after 72 hrs by MTT assay	[PMID: 18930407]
HeLa	IC₅₀	3.56 μM Compound: 19	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25350923]
HepG2	IC₅₀	12.2 μM Compound: JS-K	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23617697]
HepG2	IC₅₀	5.19 μM Compound: JS-K	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23617697]
HepG2	IC₅₀	7.12 μM Compound: JS-K	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23617697]
HepG2	IC₅₀	7.42 μM Compound: JS-K	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
HL-60	IC₅₀	0.2 μM Compound: JS-K	Antiproliferative activity against human HL-60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 18930407]
HL-60	IC₅₀	0.2 μM Compound: JS-K	Antiproliferative activity against human HL60 cells after 24 hrs Antiproliferative activity against human HL60 cells after 24 hrs	[PMID: 19364650]
HL-60	IC₅₀	0.2 μM Compound: JS-K	Antiproliferative activity against human HL60 cells assessed as decrease in cell viability measured after 3 days by MTT assay Antiproliferative activity against human HL60 cells assessed as decrease in cell viability measured after 3 days by MTT assay	[PMID: 28505442]
HL-60	IC₅₀	0.2 μM Compound: JS-K	Antileukemic activity in human HL60 cells assessed as nitric oxide release Antileukemic activity in human HL60 cells assessed as nitric oxide release	[PMID: 18178089]
HL-60	IC₅₀	0.5 μM Compound: 2a	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16821795]
HL-60	IC₅₀	0.53 μM Compound: 6; JS-K	Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
HT-29	IC₅₀	0.8 μM Compound: JS-K	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 18930407]
hTERT-BJ	IC₅₀	10 μM Compound: JS-K	Antiproliferative activity against human BJ-5ta cells after 72 hrs by MTT assay Antiproliferative activity against human BJ-5ta cells after 72 hrs by MTT assay	[PMID: 18930407]
HUVEC	IC₅₀	5.39 μM Compound: 19	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 25350923]
Jurkat E6.1	IC₅₀	0.92 μM Compound: JS-K	Anticancer activity against human Jurkat E6-1 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay Anticancer activity against human Jurkat E6-1 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay	[PMID: 32156499]
L02	IC₅₀	1.99 μM Compound: 6; JS-K	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
MCF-10A	IC₅₀	4.91 μM Compound: JS-K	Antiproliferative activity against human MCF10A cells after 48 hrs by MTT assay relative to control Antiproliferative activity against human MCF10A cells after 48 hrs by MTT assay relative to control	[PMID: 29220794]
MCF7	IC₅₀	993 nM Compound: 1; JS-K	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29420887]
MDA-MB-231	IC₅₀	2.9 μM Compound: 6; JS-K	Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
MDA-MB-231	IC₅₀	5.75 μM Compound: JS-K	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay relative to control Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay relative to control	[PMID: 29220794]
MDA-MB-231	IC₅₀	7.93 μM Compound: JS-K	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay	[PMID: 32156499]
NCI-H1373	IC₅₀	0.86 μM Compound: 1, JS-K	Antiproliferative activity against human NCI-H1373 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1373 cells after 72 hrs by MTT assay	[PMID: 22003962]
NCI-H1703	IC₅₀	0.57 μM Compound: 1, JS-K	Antiproliferative activity against human NCI-H1703 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1703 cells after 72 hrs by MTT assay	[PMID: 22003962]
NCI-H1703	IC₅₀	1.08 μM Compound: 1, Js-K	Antiproliferative activity against human NCI-H1703 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1703 cells after 48 hrs by MTT assay	[PMID: 22480849]
NCI-H1944	IC₅₀	>10 μM Compound: 1, JS-K	Antiproliferative activity against human NCI-H1944 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1944 cells after 72 hrs by MTT assay	[PMID: 22003962]
NCI-H2122	IC₅₀	3.17 μM Compound: 1, JS-K	Antiproliferative activity against human NCI-H2122 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H2122 cells after 72 hrs by MTT assay	[PMID: 22003962]
NCI-H441	IC₅₀	0.94 μM Compound: 1, JS-K	Antiproliferative activity against human NCI-H441 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H441 cells after 72 hrs by MTT assay	[PMID: 22003962]
NCI-H441	IC₅₀	1 μM Compound: JS-K	Antiproliferative activity against human H441 cells after 72 hrs by MTT assay Antiproliferative activity against human H441 cells after 72 hrs by MTT assay	[PMID: 18930407]
NCI-H838	IC₅₀	4.3 μM Compound: JS-K	Antiproliferative activity against human H838 cells after 72 hrs by MTT assay Antiproliferative activity against human H838 cells after 72 hrs by MTT assay	[PMID: 18930407]
OVCAR-3	IC₅₀	>20 μM Compound: JS-K	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 36470106]
OVCAR-3	IC₅₀	0.8 μM Compound: JS-K	Antiproliferative activity against human OVCAR-3 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR-3 cells after 72 hrs by MTT assay	[PMID: 18930407]
OVCAR-5	IC₅₀	1 μM Compound: JS-K	Antiproliferative activity against human OVCAR5 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR5 cells after 72 hrs by MTT assay	[PMID: 18930407]
Panel NCI-51 (51 carcinoma cell lines)	GI₅₀	1.32 μM Compound: 2a	Antiproliferative activity against human NCI51 cell line Antiproliferative activity against human NCI51 cell line	[PMID: 16821795]
PC-3	IC₅₀	1.1 μM Compound: JS-K	Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay	[PMID: 18930407]
SK-OV-3	IC₅₀	18.5 μM Compound: JS-K	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 36470106]
SMMC-7721	IC₅₀	7.31 μM Compound: JS-K	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 23617697]
SW-620	IC₅₀	5.16 μM Compound: JS-K	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
SW626	IC₅₀	>20 μM Compound: JS-K	Antiproliferative activity against human SW626 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human SW626 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 36470106]
TK-10	IC₅₀	0.5 μM Compound: JS-K	Antiproliferative activity against human TK-10 cells after 72 hrs by MTT assay Antiproliferative activity against human TK-10 cells after 72 hrs by MTT assay	[PMID: 18930407]
U2OS	IC₅₀	6.27 μM Compound: JS-K	Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay relative to control Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay relative to control	[PMID: 29220794]
U-937	IC₅₀	0.3 μM Compound: JS-K	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 18930407]
U-937	IC₅₀	0.3 μM Compound: JS-K	Antiproliferative activity against human U937 cells after 24 hrs Antiproliferative activity against human U937 cells after 24 hrs	[PMID: 19364650]
Vero	IC₅₀	1.16 μM Compound: 6; JS-K	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]

In Vitro

JS-K (0-5 μM, 3 d) inhibits proliferation of HL-60 (IC₅₀: 0.5 μM), PPC-1, DLD-1, Meth A, U937 (IC₅₀: 0.3 μM) cells^[1].
JS-K (0.5 μM, 5 d) leads to HL-60 cells differentiation and acquires some of the phenotypic features of normal monocytes^[1].
JS-K (0.5-1 μM, 3 d) induces apoptosis in a concentration and caspase-dependent manner in HL-60 cells^[1].
JS-K (12.5-5 μM, 24 h) significantly increases the production of ROS/RNS in a concentration-dependent manner, and the effect is reversed by N-acetyl-L-cysteine (NAC) (HY-B0215) in A2780 and SKOV3 cells^[2].
JS-K (12.5-5 μM, 24 h) induces autophagy in A2780 and SKOV3 cells^[2].
JS-K (0.5-1 μM, 72 h) inhibits breast cancer invasion across the Matrigel basement membrane, and NO production is vital for this activity. blocking TIMP-2 activity significantly suppressed the anti-invasive effects of JS-K^[3].
JS-K (1-10 μM， 24 h) activates apoptosis pathways in Hep3B cells, including induction of caspase-3, caspase-9, Bax, TNF-α, and IL-1β^[4].
JS-K (1-10 μM， 24 h) increases thrombospondin-1 (TSP-1) and the metalloproteinase-1 (TIMP-1) at both transcript and protein levels. JS-K increases the expression of differentiation-related genes CD14 and CD11b, and depresses the expression of c-myc^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

HL-60
Concentration:

0.5, 0.75, 1 μM
Incubation Time:

3 d
Result:

(0.5, 1 μM) Increased percentage of apoptotic from 7 to 27 and 43%, respectively.
(0.75 μM) Pan-caspase inhibitor CVAD-FMK prevented the growth inhibitory and apoptotic effects.

Cell Autophagy Assay^[2]

Cell Line:

A2780 and SKOV3 cells
Concentration:

1.25, 2.5, 5 μM
Incubation Time:

24 h
Result:

Expression of LC3BII and ATG5 proteins increased, while p62 mRNA level decreased and protein level expression decreased in a concentration-dependent manner.
Induce a greater accumulation of autophagosomes in SKOV3 cells, indicating a disruption in the last step of autophagy in which autophagosomes fuse with lysosomes and the cellular content is degraded.

Cell Invasion Assay^[3]

Cell Line:

MDA-MB-231, F10, MCF-7/COX-2
Concentration:

0.5, 1 μM
Incubation Time:

72 h
Result:

At the 0.5 and 1 μM doses, the number of invaded cells was decreased 37% and 85% in MDA-MB-231, 63% and 76% in F10, 49% and 75% in MCF-7/COX-2, respectively.
At the 0.5 and 1 μM doses, TIMP-2 levels were increased 1.9-fold and threefold in MDA-MB-231, 1.5-fold and 7.2-fold in F10 cells, respectively. And twofold in MCF-7/COX-2 cells at the 1 μM dose.
In the absence and presence of the anti-TIMP-2 antibody, (1 μM) decreased the number of invaded cells by 72% and 37% in MDA-MB- 231, 72% and 40% in F10, 65% and 30% in MCF-7/COX-2 cells.

Western Blot Analysis^[2]

Cell Line:

SKOV3 cells
Concentration:

2.5 μM
Incubation Time:

24 h
Result:

LC3BII, BAX, P62 and Bcl2 proteins were found to be elevated in cells co-treated with BAF.

In Vivo

JS-K (1.54 mg/kg; i.v.; three times/week for 15-20 days) reduces tumor volume and causes necrosis of implanted tumors in mice ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID mice (6-8 weeks) (injected in the flanks s.c. with HL-60 or PPC-1 cells)^[1]
Dosage:

1.54 mg/kg
Administration:

Intravenous injection (i.v.), three times/week for 15-20 days
Result:

Sixteen days after starting therapy, the average tumor volumes in vehicle and experimental group were 8.34 and 3.13 cm³, respectively, reflecting a > 50% reduction in tumor volume in experimental group.
Nineteen days after start of therapy, s.c. tumor implant volumes were 0.368 and 0.107 cm³ in vehicle and experimental group, respectively.
Revealed extensive cell necrosis in HL-60 (> 50%) and PPC-1 cell tumors.
Up to 1.54 mg/kg without observing significant hypotension, whereas doses of 1.54 mg/kg or higher has a notable hypotensive effect.

Chemical Information

CAS No. 205432-12-8
Appearance Solid
Masse moléculaire 384.30
Formule C₁₃H₁₆N₆O₈
Color White to yellow
SMILES

O=C(N1CCN(/[N+]([O-])=N/OC2=CC=C([N+]([O-])=O)C=C2[N+]([O-])=O)CC1)OCC
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : 36 mg/mL (93.68 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6021 mL

13.0107 mL

26.0213 mL

5 mM

0.5204 mL

2.6021 mL

5.2043 mL

10 mM

0.2602 mL

1.3011 mL

2.6021 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Shami PJ, et al. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther. 2003 Apr;2(4):409-17. [Content Brief]

[2]. Liu B, et al. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer. BMC Cancer. 2019 Jul 1;19(1):645. [Content Brief]

[3]. Simeone AM, et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 2008;10(3):R44. [Content Brief]

[4]. Dong R, et al. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells. Biomed Pharmacother. 2017 Apr;88:367-373. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6021 mL	13.0107 mL	26.0213 mL	65.0533 mL
	5 mM	0.5204 mL	2.6021 mL	5.2043 mL	13.0107 mL
	10 mM	0.2602 mL	1.3011 mL	2.6021 mL	6.5053 mL
	15 mM	0.1735 mL	0.8674 mL	1.7348 mL	4.3369 mL
	20 mM	0.1301 mL	0.6505 mL	1.3011 mL	3.2527 mL
	25 mM	0.1041 mL	0.5204 mL	1.0409 mL	2.6021 mL
	30 mM	0.0867 mL	0.4337 mL	0.8674 mL	2.1684 mL
	40 mM	0.0651 mL	0.3253 mL	0.6505 mL	1.6263 mL
	50 mM	0.0520 mL	0.2602 mL	0.5204 mL	1.3011 mL
	60 mM	0.0434 mL	0.2168 mL	0.4337 mL	1.0842 mL
	80 mM	0.0325 mL	0.1626 mL	0.3253 mL	0.8132 mL

Bioz

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

JS-K

S-Nitroso-N-acetyl-DL-penicillamine

DMPO

4β-Hydroxywithanolide E

Nitrosoglutathione

MAHMA NONOate

L-Arginine

Dipropylenetriamine NONOate

Isocurcumenol

9-β-D-Arabinofuranosylguanine

Carboxy-PTIO potassium

V-PYRRO/NO

L-Arginine (Standard)

Voir tous les produits spécifiques à Isoform NO Synthase

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

JS-K

S-Nitroso-N-acetyl-DL-penicillamine

DMPO

4β-Hydroxywithanolide E

Nitrosoglutathione

MAHMA NONOate

L-Arginine

Dipropylenetriamine NONOate

Isocurcumenol

9-β-D-Arabinofuranosylguanine

Carboxy-PTIO potassium

V-PYRRO/NO

L-Arginine (Standard)

Voir tous les produits spécifiques à Isoform NO Synthase

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

JS-K Related Classifications

HY-126193 Related Classifications

Bioz